Tenet Healthcare's Q2 results demonstrated strong growth driven by its Ambulatory segment, which successfully offset a decline in patient days. The company reported a 43.5% increase in non-GAAP EPS and subsequently raised its FY2026 guidance for revenue and free cash flow. Additionally, Tenet announced a $2 billion increase in its share repurchase authorization while maintaining a 'Strong Buy' rating from most market analysts.
The company reported a 43.5% surge in EPS driven by its ambulatory segment, while boosting revenue and free cash flow targets.
Read the full storyAnalysts project earnings and revenue growth for Tenet Healthcare while maintaining bullish ratings despite rising physician staffing costs.
Analysts expect higher revenue per admission and ambulatory care growth to balance pressures from declining patient hospital stays in the second quarter.